Dupilumab: Basic aspects and applications to allergic diseases.

07:00 EST 29th January 2020 | BioPortfolio

Summary of "Dupilumab: Basic aspects and applications to allergic diseases."

Interleukin (IL)-4 and IL-13, signature type 2 cytokines, exert their actions by binding to two types of receptors sharing the IL-4R α chain (IL-4Rα). Since IL-4 and IL-13 play important and redundant roles in the pathogenesis of allergic diseases, blocking both the IL-4 and IL-13 signals would be a powerful and effective strategy for treating allergic diseases. Dupilumab (Dupixent®) is a fully human monoclonal antibody recognizing IL-4Rα and blocking both the IL-4 and IL-13 signals. Dupilumab was first prescribed for atopic dermatitis (AD) patients and has been widely approved for adult patients with moderate to severe AD since 2018. Dupilumab has since been used for asthma, receiving approval for uncontrolled asthma in 2019. A phase 3 study using dupilumab for chronic rhinosinusitis with nasal polyps (CRSwNP) has been just completed, with positive results. Several clinical trials of dupilumab for other diseases in which type 2 inflammation is dominant are now underway. It is hoped that dupilumab will open the door to a new era for treating allergic patients with AD, asthma, and CRSwNP, and for more patients with type 2 inflammations.


Journal Details

This article was published in the following journal.

Name: Allergology international : official journal of the Japanese Society of Allergology
ISSN: 1440-1592


DeepDyve research library

PubMed Articles [17796 Associated PubMed Articles listed on BioPortfolio]

Mechanisms of Dupilumab.

The Th2 cytokines interleukin 4 (IL-4) and IL-13 and the heterodimeric IL-4 receptor (IL-4R) complexes that they interact with play a key role in the pathogenesis of allergic disorders. Dupilumab is a...

Dupilumab in Dermatology: Potential for Uses Beyond Atopic Dermatitis

Dupilumab inhibits the interleukin-4 receptor subunit α and is FDA approved for treatment of moderate-to-severe atopic dermatitis. It is a relatively new drug, and whether it is efficacious for other...

Dupilumab Efficacy in Patients With Uncontrolled, Moderate-to-Severe Allergic Asthma.

Dupilumab blocks the shared receptor component for interleukin-4 and interleukin-13, key drivers of type 2 inflammation, including immunoglobulin E (IgE)-mediated allergic inflammation in asthma. In t...

New biological treatments for asthma and skin allergies.

Allergies are typically endemic, complex and heterogeneous diseases with a high impact at quality of life. Mechanistically, type 2 immune responses involving eosinophil and basophil granulocytes, mast...

Biologics in Children with Allergic Diseases.

The prevalence of allergic diseases prevalence has been remarkably increased in the last decades. The global health burden of these conditions is substantial, since patients may experience disability,...

Clinical Trials [6388 Associated Clinical Trials listed on BioPortfolio]

Study of REGN3500 and Dupilumab in Patients With Asthma

To assess the effects of REGN3500, dupilumab, REGN3500 and dupilumab compared with placebo, on inflammatory gene expression after a bronchial allergen challenge (BAC) in adults with mild a...

Dupilumab As An Adjunct For Subcutaneous Grass Immunotherapy

The primary objective is to assess whether 16 weeks of treatment with dupilumab as an adjunct to Timothy Grass Subcutaneous Immunotherapy (SCIT) improves upon the efficacy of Timothy Grass...

A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid

The primary objective of the study is to demonstrate that dupilumab is superior to placebo in achieving sustained remission off oral corticosteroids (OCS) in patients with bullous pemphigo...

The Effects of Dupilumab on Allergic Contact Dermatitis

The aim of this study is to investigate the effects of dupilumab on allergic contact dermatitis.

Study to Evaluate the Efficacy and Safety of Dupilumab Monotherapy in Pediatric Patients With Peanut Allergy

The primary objective of the study is to assess whether dupilumab as compared to placebo improves peanut protein tolerability, defined as an increase in the proportion of patients who safe...

Medical and Biotech [MESH] Definitions

A group of 7 proteins produced from a single gene by alternate splicing found in central and peripheral nervous system myelin. The major basic protein (MBP) has long been of interest because it is the antigen, that, when injected into an animal, elicits a cellular immune response that produces the CNS autoimmune disease called experimental allergic encephalomyelitis (ENCEPHALOMYELITIS, ALLERGIC). In the peripheral nervous system, myelin basic protein 18.5-kDa is often referred to as the P1 protein. (From Siegel et al., Basic Neurochemistry, 5th ed, p130, 133)

Component of the NATIONAL INSTITUTES OF HEALTH. It conducts and supports basic and applied research to better understand, treat, and ultimately prevent infectious, immunologic, and allergic diseases. It was established in 1948.

A positively charged protein found in peripheral nervous system myelin. Sensitive immunological techniques have demonstrated that P2 is expressed in small amounts of central nervous system myelin sheaths of some species. It is an antigen for experimental allergic neuritis (NEURITIS, EXPERIMENTAL ALLERGIC), the peripheral nervous system counterpart of experimental allergic encephalomyelitis. (From Siegel et al., Basic Neurochemistry, 5th ed, p133)

A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than PROMETHAZINE.

Allergic rhinitis that occurs at the same time every year. It is characterized by acute CONJUNCTIVITIS with lacrimation and ITCHING, and regarded as an allergic condition triggered by specific ALLERGENS.

Quick Search

DeepDyve research library

Relevant Topics

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...

An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Eczema is a common itchy skin disease characterized by reddening and vesicle formation, which may lead to weeping and crusting. It is endogenous, or constitutional. There are five main types; atopic, seborrhoeic, discoid, gravitational or varicose. ...

Searches Linking to this Article